Early COPERNICUS results show subcutaneous amivantamab and proactive VTE and skin prophylaxis sharply reduce reactions, helping NSCLC patients stay on therapy.
Rethinking the Amivantamab Experience: What the COPERNICUS Data Mean for Practice in Non-Small Cell Lung Cancer
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Cancer Surgery Waiting Times Rising: What Oncology Nurses Need to Know
2
Nurse-Led Strategies for Vitamin D in Cancer Care
3
How An Adaptive Weight-Loss Strategy Benefits Breast Cancer Survivors
4
Using Biomarker Testing to Personalize Metastatic Triple-Negative Breast Cancer Care
5